886499-74-7

Basic information

• Product Name: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID
• Synonyms: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID;3-[4-(Trifluoromethoxy)phenyl]propanoic acid;4-(Trifluoromethoxy)hydrocinnamic acid, 3-[4-Trifluoromethoxy)phenyl]propionic acid;4-(Trifluoromethoxy)hydrocinnemic acid;4-(TRIFLUOROMETHOXY)HYDROCINNAMIC ACID
• CAS NO: 886499-74-7
• Molecular Formula: C₁₀H₉F₃O₃
• Molecular Weight: 234.17
• Product Categories: Aromatic Propionic Acids
• Mol File: 886499-74-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID(886499-74-7)
• EPA Substance Registry System: 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID(886499-74-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• WGK Germany: 3
• Hazardous Substances Data: 886499-74-7(Hazardous Substances Data)

Usage

General Description

2-(4-Trifluoromethoxyphenyl)propionic acid is a chemical compound with the molecular formula C10H9F3O3. It is a nonsteroidal anti-inflammatory drug (NSAID) that is often used to relieve pain and reduce inflammation. It works by inhibiting the production of certain chemicals in the body that cause pain and inflammation. 2-(4-TRIFLUOROMETHOXYPHENYL)PROPIONIC ACID is commonly used to treat conditions such as arthritis, menstrual cramps, and other types of chronic pain. It is typically taken orally and is available in various forms, such as tablets and capsules. Despite its therapeutic benefits, 2-(4-Trifluoromethoxyphenyl)propionic acid can cause side effects such as stomach irritation, heartburn, and gastrointestinal bleeding, and it may also increase the risk of heart attack and stroke, particularly when used at high doses or for long periods.

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 659-28-9 p-trifluoromethoxybenzaldehyde 

Downstream Products

• 1000519-40-3 3-(4-trifluoromethoxyphenyl)propan-1-ol 
• 1613696-23-3 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-{2-[4-(trifluoromethoxy)phenyl]ethyl}-1H-benzimidazole 
• 1412452-77-7 C₂₁H₂₁F₃N₄O₃ 
• 1412452-76-6 C₂₀H₂₁F₃N₄O₄ 
• 1412452-70-0 2-(ethylamino)-6-(3-(4-(trifluoromethoxy)phenyl)propanoyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-4-carboxamide 
• 1026522-08-6 5-[2-(5-chloro-2-methoxybenzamido)ethyl]-2-(trifluoromethoxy)benzenesulfonamide 
• 1027243-82-8 5-chloro-2-methoxy-N-(2-(4-trifluoromethoxyphenyl)ethyl)benzamide 
• 1026038-41-4 N-Boc-4-(trifluoromethoxy)phenylethylamine 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES

The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I),wherein X represents CH2 or O; R1 represents a phenyl group, which group is independently mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, trifluoromethoxy and trifluoromethyl; R2 represents (C1-4)alkyl, (C1-4)alkoxy, (C2-4)alkenyl, halogen, cyano, hydroxymethyl, trifluoromethyl, C(O)NR5R6 or cyclopropyl; R3 represents (C1-4)alkyl, (C1-4)alkoxy-methyl or halogen; R4 represents (C1-4)alkyl; R5 represents hydrogen or (C1-4)alkyl; and R6 represents hydrogen or (C1-4)alkyl. The invention also relates to pharmaceutically acceptable salts of such compounds; and to the use of such compounds as medicaments; especially as orexin receptor antagonists.